Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users

Drug and Alcohol Dependence

Volumn 140, Issue , 2014, Pages 69-77

  Nosyk, B ^a,b,c   Li, L ^c   Evans, E ^c   Huang, D ^c   Min, J ^a   Kerr, T ^a,d   Brecht, M L ^c   Hser, Y I ^c  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Drug use careers; Health state transitions; Longitudinal; Multi state Markov; Proportional hazards frailty

Indexed keywords

COCAINE; DIAMORPHINE; METHAMPHETAMINE; CENTRAL STIMULANT AGENT;

ABSTINENCE; ADOLESCENT; ADULT; ARTICLE; COCAINE DEPENDENCE; COHORT ANALYSIS; CONTROLLED STUDY; CRIMINAL BEHAVIOR; FEMALE; HEALTH STATUS; HEROIN DEPENDENCE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METHAMPHETAMINE DEPENDENCE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PRISON; UNITED STATES; COCAINE-RELATED DISORDERS; CRIME; DRUG ABUSE; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

ADULT; AMPHETAMINE-RELATED DISORDERS; CALIFORNIA; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE-RELATED DISORDERS; COHORT STUDIES; CRIME; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HEROIN DEPENDENCE; HUMANS; LONGITUDINAL STUDIES; MALE; METHAMPHETAMINE; MIDDLE AGED; SOCIOECONOMIC FACTORS;

EID: 84924849667     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.03.029     Document Type: Article

References (63)

1. Amato L., Davoli M., Perucci C.A., Ferri M., Faggiano F., Mattick R.P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J. Subst. Abuse Treat. 2005, 28:321-329.
2. Anglin M.D., Hser Y.I., Chou C. Reliability and validity of retrospective behavioral self-report by narcotics addicts. Eval. Rev. 1993, 17:91-108.
3. Balster R.L., Singleton J., Degenhardt L., Hall W., Zabransky T. Mortality among amphetamine users: a systematic review of cohort studies. Drug Alcohol Depend. 2009, 105:1-8.
4. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J. Addict. Dis. 2012, 31:207-225.
5. Bell J., Burrell T., Indig D., Gilmour S. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. Drug Alcohol Depend. 2006, 81:55-61.
6. Boeri M., Whalen T., Tyndall B., Ballard E. Drug use trajectory patterns among older drug users. Subst. Abuse Rehabil. 2011, 2:89-102.
7. Bovasso G., Cacciola J. The long-term outcomes of drug use by methadone maintenance patients. J. Behav. Health Serv. Res. 2003, 30:290-303.
8. Brackins T., Brahm N.C., Kissack J.C. Treatments for methamphetamine abuse: a literature review for the clinician. J. Pharm. Pract. 2011, 24:541-550.
9. Brecht M.L., Huang D., Evans E., Hser Y.-I. Polydrug use and implications for longitudinal research: ten-year trajectories for heroin, cocaine, and methamphetamine users. Drug Alcohol Depend. 2008, 96:193-201.
10. Brecht M.L., O'Brien A., Mayrhauser C., Anglin M.D. Methamphetamine use behaviors and gender differences. Addict. Behav. 2004, 29:89-106.
11. Briggs A., Sculpher M., Claxton K. Decision modelling for health economic evaluation. Economic Evaluation in Clinical Trials 2006, 45-76. Oxford University Press, Oxford. H.A. Glick, J.A. Doshi, S.S. Seema, D. Polsky (Eds.).
12. Buck J.A. The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Aff. 2011, 30:1402-1410.
13. Chou C.P., Hser Y.I., Anglin M.D. Pattern reliability of narcotics addicts' self-reported data: a confirmatory assessment of construct validity and consistency. Subst. Use Misuse 1996, 31:1189-1216.
14. Cook R.J., Lawless J.F. The Statistical Analysis of Recurrent Events 2007, Springer, New York.
15. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M., McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011, 106:32-51.
16. Degenhardt L., Singleton J., Calabria B., McLaren J., Kerr T., Mehta S., Kirk G., Hall W.D. Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend. 2011, 113:88-95.
17. Dennis M.L., Scott C.K., Funk R., Foss M.A. The duration and correlates of addiction and treatment careers. J. Subst. Abuse Treat. 2005, 28:S51-S62.
18. Dobler-Mikola A., Hattenschwiller J., Meili D., Beck T., Boni E., Modestin J. Patterns of heroin, cocaine and alcohol abuse during long-term methadone maintenance treatment. J. Subst. Abuse Treat. 2005, 29:259-265.
19. Evans E., Li L., Grella C., Brecht M.L., Hser Y.I. Developmental timing of first drug treatment and 10-year patterns of drug use. J. Subst Abuse Treat. 2013, 44:271-279.
20. Friedmann P.D., Hoskinson R., Stein L.A.R., Gordon M., Schwartz R., Kinlock T., Knight K., Flynn P.M., Welsh W.N., Sacks S., Oconnell D.J., Knudsen H.K., Shafer M.S., Hall E., Frisman L.K. Medication-assisted treatment in criminal justice agencies affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): availability, barriers, and intentions. Subst. Abuse 2012, 33:9-18.
21. Galai N., Safaeian M., Vlahov D., Bolotin A., Celetano D.D. Longitudinal patterns of drug injection behaviour in the ALIVE study cohort, 1988-2000: description and determinants. Am. J. Epidemiol. 2003, 158:695-704.
22. Genberg B.L., Gange S.J., Go V.F., Celentano D.D., Kirk G.D., Latkin C.A., Mehta S.H. The effect of neighborhood deprivation and residential relocation on long-term injection cessation among Injection Drug Users (IDUs) in Baltimore, Maryland. Addiction 2011, 106:1966-1974.
23. Grambsch P.M., Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
24. Grella C.E., Lovinger K. 30-year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California. Drug Alcohol Depend. 2011, 118:251-258.
25. Grimes D.A., Schulz K.F. Bias and causal associations in observational research. Lancet 2002, 359:248-252.
26. Hser Y.I., Anglin M.D., Chou C. Reliability of retrospective self-report by narcotics addicts. Psychol. Assess. 1992, 4:207-213.
27. Hser Y.I., Evans E., Huang D., Brecht M.L., Li L. Comparing the dynamic course of heroin, cocaine, and methamphetamine use over 10 years. Addict. Behav. 2008, 33:1581-1590.
28. Hser Y.I., Hoffman V., Grella C.E., Anglin M.D. A 33-year follow-up of narcotics addicts. Arch. Gen. Psychiatry 2001, 58:503-508.
29. Hser Y.I., Huang D., Brecht M.L., Li L., Evans E. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J. Addict. Dis. 2008, 27:13-21.
30. Hser Y.I., Huang D., Teruya C., Anglin M.D. Gender differences in drug abuse treatment outcomes and correlates. Drug Alcohol Depend. 2003, 72:255-264.
31. Hser Y.I., Huang D., Teruya C., Anglin M.D. Diversity of drug abuse treatment utilization patterns and outcomes. Eval. Program Plann. 2004, 27:309-319.
32. Hser Y.I., Longshore D., Anglin M.D. The life course perspective on drug use: a conceptual framework for understanding drug use trajectories. Eval. Rev. 2007, 31:515-547.
33. Hser Y.I., Stark M.E., Paredes A., Huang D., Anglin M.D., Rawson R. A 12-year follow-up of a treated cocaine-dependent sample. J. Subst. Abuse Treat. 2006, 30:219-226.
34. Jackson C.H. Multi-state models for panel data: the MSM package for R. J. Stat. Softw. 2011, 38:1-28.
35. Juon H.S., Fothergill K.E., Green K.M., Doherty E.E., Ensminger M.E. Antecedents and consequences of marijuana use trajectories over the life course in an African American population. Drug Alcohol Depend. 2011, 118:216-223.
36. Kubiak S.P., Arfken C.L., Swartz J.A., Koch A.L. Treatment at the front end of the criminal justice continuum: the association between arrest and admission into specialty substance abuse treatment. Subst. Abuse Treat. Prev. Policy 2006, 1:20.
37. Li L., Evans E., Hser Y.I. A marginal structural modeling approach to assess the cumulative effect of drug treatment on later drug use abstinence. J. Drug Issues 2010, 40:221-240.
38. Liang L.J., Huang D., Brecht M.L., Hser Y.I. Differences in mortality among heroin, cocaine and methamphetamine users: a hierarchical Bayesian approach. J. Drug Issues 2010, 40:121-140.
39. McGlothlin W.H., Anglin M.D., Wilson B.D. An Evaluation of the California Civil Addict Program 1977, National Institute on Drug Abuse. Services Research Monograph Series. DHEW Publication No. (ADM) 78-558. U.S. Government Printing Office, Rockville/Washington, DC.
40. McLellan A.T. Have we evaluated addiction treatment correctly? Implications from a chronic care perspective. Addiction 2002, 97:249-252.
41. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689-1695.
42. Murphy D., Hser Y., Huang D., Brecht L., Herbeck D.M. Self-report of longitudinal substance use: a comparison of the UCLA Natural History Interview and the Addiction Severity Index. J. Drug Issues 2010, 40:495-516.
43. Nosyk B., Anglin M.D., Brecht M.L., Lima V.D., Hser Y.I. Characterizing durations of heroin abstinence in California Civil Addict Program: results from a 33-year observational cohort study. Am. J. Epidemiol. 2013, 177:675-682.
44. Nosyk B., Guh D.P., Bansback N.J., Oviedo-Joekes E., Brissette S., Marsh D.C., Meikleham E., Schechter M.T., Anis A.H. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ 2012, 184:E317-E328.
45. Nosyk B., MacNab Y.C., Sun H., Fischer B., Marsh D.C., Schechter M.T., Anis A.H. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am. J. Epidemiol. 2009, 170:783-792.
46. Nurco D.N., Bonito A.J., Lerner M., Balter M.B. Studying addicts over time: methodology and preliminary findings. Am. J. Drug Alcohol Abuse 1975, 2:183-196.
47. R Development Core Team R: A Language and Environment for Statistical Computing 2012, R Foundation for Statistical Computing, Vienna.
48. Raudenbush S.W., Bryk A.S. Hierarchical Linear Models: Applications and Data Analysis Methods 2002, Sage, Newbury Park.
49. Rich J.D., Wohl D.A., Beckwith C.G., Spaulding A.C., Lepp N.E., Baillargeon J., Gardner A., Avery A., Altice F.L., Springer S. HIV-related research in correctional populations: now is the time. Centers for AIDS Research - Collaboration on HIV in Corrections Working Group. Curr. HIV/AIDS Rep. 2011, 8:288-296.
50. Ross S., Peselow E. Pharmacotherapy of addictive disorders. Clin. Neuropharmacol. 2009, 32:277-289.
51. Sargent D.J. A general framework for random effects survival analysis in the cox proportional hazards setting. Biometrics 1998, 54:1486-1497.
52. Schnittker J., John A. Enduring stigma: the long-term effects of incarceration on health. J. Health Soc. Behav. 2007, 48:115-130.
53. Scott C.K., Foss M.A., Dennis M.L. Pathways in the relapse-treatment - recovery cycle over 3 years. J. Subst. Abuse Treat. 2005, 28:S63-S72.
54. Sculpher M.J., Claxton K., Drummond M., McCabe C. Whither trial-based economic evaluation for health care decision making?. Health Econ. 2006, 15:677-687.
55. Shearer J. Psychosocial approaches to psychostimulant dependence: a systematic review. J. Subst. Abuse Treat. 2007, 32:41-52.
56. Termorshuizen F., Krol A., Prins M., Geskus R., van den Brink W., van Ameijden E.J. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend. 2005, 79:231-240.
57. Termorshuizen F., Krol A., Prins M., van Ameijden E.J. Long-term outcome of chronic drug use: the Amsterdam Cohort Study among drug users. Am. J. Epidemiol. 2005, 161:271-279.
58. Vaida F., Xu R. Proportional hazards model with random effects. Stat. Med. 2000, 19:3309-3324.
59. Vocci F.J., Acri J., Elkashef A. Medication development for addictive disorders: the state of the science. Am. J. Psychiatry 2005, 162:1432-1440.
60. Vocci F.J., Montoya I.D. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr. Opin. Psychiatry 2009, 22:263-268.
61. Weinstein M.C., O'Brien B., Hornberger J., Jackson J., Johannesson M., McCabe C., Luce B.R. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003, 6:9-17.
62. Zaric G.S., Barnett P.G., Brandeau M.L. HIV transmission and the cost-effectiveness of methadone maintenance. Am. J. Public Health 2000, 90:1100-1111.
63. Zarkin G.A., Dunlap L.J., Hicks K.A., Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005, 14:1133-1150.